# MapLight Therapeutics Inc. (MPLT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $13.77, market value $639 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). MapLight Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 1.8×**. The shares trade at 1.8× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -21.7%** (5-yr avg -90.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -35.2%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 82.4%**. Earnings per share rose 82.4%.

## Financial health
- **Current ratio: 20.01** (quick 20.01). Current assets cover the next year's liabilities 20.01 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. MapLight Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (13 analysts). 13 analysts cover MapLight Therapeutics Inc.; the consensus is strong_buy, with an average price target of $26.54 (+93% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -65.9%** (51.3% above the low). Trading 66% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 44**. An RSI of 44 is neutral.
- **Beta (1 yr): 0.94** (volatility 119%). Beta of 0.94 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MPLT · Page: https://foliofundamentals.com/stocks/mplt

Not investment advice.